Telecommunications & Broadcasting

ktcs corporation Reports Record-High Third-Quarter Operating Profit… Increases Dividends and Retires All Treasury Stock

Third-Quarter Operating Profit of 11 Billion Won… Up 42.5% Year-Over-Year 40% of Adjusted Net Income to Be Returned to Shareholders… Minimum Annual Dividend of 140 Won Dividends to Be Paid Twice a Year Starting in 2027… 3.46 Million Treasury Shares to Be Canceled

Kim Hyun-ah
2026-11-09 08:00:00
[Edaily Reporter Kim Hyun-ah ] ktcs corporation(058850)posted its highest-ever operating profit in the third quarter of this year. Building on this improved performance, the company is introducing a medium-term shareholder return policy for the first time since its founding and will proceed with increased dividends and the cancellation of all treasury shares.

ktcs corporation announced on the 6th that its operating profit for the third quarter of this year, based on separate financial statements, was 11.04 billion won, a 42.5% increase compared to the same period last year. Cumulative operating profit for the first three quarters also reached 26.27 billion won, up 24.8% year-over-year, marking a record high.



The company explained that efforts to improve profitability—including operational efficiency and cost reductions in the contact center business—led to the increase in earnings.

ktcs corporation held a board meeting that day and approved a medium-term shareholder return policy to be implemented from 2026 to 2028. This is the first medium-term policy established since the company’s founding, and its purpose is to enhance predictability for investors by outlining the scale of shareholder returns and dividend criteria in advance.

The company set the funding for shareholder returns at 40% of adjusted net income on a separate basis, excluding one-time non-recurring gains and losses. Returns to shareholders will be made through cash dividends and the repurchase and cancellation of treasury stock.

The minimum annual dividend per share is 140 won. The previous dividend was 120 won in 2022 and 100 won annually from 2023 through 2025. The 140 won represents the highest level since the company’s founding.

The company will also increase the frequency of dividends. Until now, it has paid only a year-end dividend, but starting in 2027, it will switch to paying dividends twice a year.

The company will also cancel all 3,465,721 shares of treasury stock it holds. With a book value of approximately 8.66 billion won, the company has decided to cancel the remaining shares following the cancellation of 1,280,550 shares in the first quarter. The cancellation represents 8.37% of the total issued shares and is scheduled to take place in December.

This cancellation will be carried out pursuant to a board resolution under Article 343 of the Commercial Act. Although the number of issued shares will decrease, there will be no change in the company’s capital.

Cho Hyun-min, Executive Vice President and Chief Financial Officer (CFO) of the ktcs corporation, stated, “This decision was made to share the company’s profits and performance with shareholders, thereby enhancing shareholder value and strengthening market confidence.” He added, “Going forward, we will continue to comprehensively consider management performance, financial structure, and market conditions to increase corporate value and shareholder value.”

Economy

Corporation

IT·Science

Economy

Xcell Therapeutics Inc. Aims to Raise 8 Billion Won by Year-End… Will It Avoid the Risk of Negative Equity?

#Xcell Therapeutics Inc. is pursuing a third-party private placement worth 7 to 8 billion won to avoid the risk of negative equity by year-end. This comes after the company raised funds through a 9.5 …
2026-11-09 08:02:02

Corporation

GemVax & KAEL Co.,Ltd. Announces Results of 72-Week Clinical Trial for ‘GV1001’ in London… Prepares for Global Phase 3 Clinical Trial Following PSP Trial

GemVax & KAEL Co.,Ltd. announced the results of a 72-week clinical trial for “GV1001,” a candidate drug for progressive supranuclear palsy (PSP), in London, UK. At the event, the company engaged with …
2026-11-09 08:35:02

IT·Science

Samsung Bioepis Confirms Equivalence in Phase 3 Clinical Trial of Keytruda Biosimilar

A Samsung Bioepis representative (left) explains the results of the global Phase 3 clinical trial for the Keytruda biosimilar “SB27” at the Society for Immunotherapy of Cancer (SITC) 2026 conference h…
2026-11-09 08:33:02